发明公开
EP3286219A1 METHODS OF TREATING PATIENTS HAVING MUTATIONS IN THE EXTRACELLULAR DOMAIN OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH A COMBINATION OF THREE FULLY HUMAN MONOCLONAL ANTI-EGFR ANTIBODIES
无效 - 撤回
基本信息:
- 专利标题： METHODS OF TREATING PATIENTS HAVING MUTATIONS IN THE EXTRACELLULAR DOMAIN OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH A COMBINATION OF THREE FULLY HUMAN MONOCLONAL ANTI-EGFR ANTIBODIES
- 申请号：EP16720651 申请日：2016-04-22
- 公开(公告)号：EP3286219A1 公开(公告)日：2018-02-28
- 发明人： ARENA SABRINA , BARDELLI ALBERTO , KEARNS JEFFREY D , WOLF BENI B , NERING RACHEL C , WANG HONGFANG
- 申请人： MERRIMACK PHARMACEUTICALS INC
- 专利权人： MERRIMACK PHARMACEUTICALS INC
- 当前专利权人： MERRIMACK PHARMACEUTICALS INC
- 优先权： US201562152707 2015-04-24; US201562244991 2015-10-22; US201662308697 2016-03-15; US201662323475 2016-04-15
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; A61K39/395 ; A61P35/00 ; C07K16/30 ; G01N33/574
摘要：
Provided herein are methods of treating an epidermal growth factor receptor (EGFR) extracellular domain (ECD) mutant cancer in a human patient by administering to the patient an oligoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody combination (e.g., MM-151, comprising a first monoclonal antibody (P1X), a second monoclonal antibody (P2X), and a third monoclonal antibody (P3X), wherein P1X, P2X and P3X are in a 2:2:1 molar ratio). In one embodiment, the cancer comprises at least one mutation in the extracellular domain of EGFR selected from the group consisting of EGFR R451C, S464L, K467T, G465R, G465E, I491M, and S492R.
IPC结构图谱:
| C | 化学；冶金 |
| --C07 | 有机化学 |
| ----C07K | 肽 |
| ------C07K16/00 | 免疫球蛋白，例如，单克隆或多克隆抗体 |
| --------C07K16/18 | .来自动物或人的抵抗物质 |
| ----------C07K16/28 | ..抗受体，细胞表面抗原或细胞表面决定因子 |